HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Attenuation of steatohepatitis, fibrosis, and carcinogenesis in mice fed a methionine-choline deficient diet by CCAAT/enhancer-binding protein homologous protein deficiency.

AbstractBACKGROUND AND AIMS:
Hepatic steatosis is a metabolic liver disease with the potential to progress to steatohepatitis, cirrhosis, and hepatocellular carcinoma (HCC). The aim of this study was to investigate the impact of CCAAT/enhancer-binding protein homologous protein (CHOP) deficiency in the development of steatosis-associated progression of HCC.
METHODS:
Eight-week-old wild-type (WT) and CHOP knockout (CHOP-/-) mice were fed a normal or methionine-choline-deficient (MCD) diet. Mice were sacrificed after 3 weeks, and steatosis, inflammation, apoptosis, and liver damage were assessed. We also evaluated fibrosis after 8 weeks of nutrition intervention. To explore the role of CHOP in liver carcinogenesis, 25 mg/kg of diethylnitrosamine (DEN) was injected intraperitoneally into 2-week-old mice, which were then fed the aforementioned diets from 8 to 24 weeks of age. CHOP expression in HCC patient livers was also evaluated.
RESULTS:
CHOP deficiency did not affect steatosis but significantly reduced apoptotic cells, inflammation scores, and serum liver enzymes. It also significantly suppressed total serum bilirubin levels, fibrotic area size, and messenger RNA expression of profibrotic cytokines. DEN-initiated carcinogenesis was promoted by the MCD diet, while CHOP deficiency significantly attenuated the total number and maximum diameter of tumors and the Ki-67 labeling index. In human livers, CHOP expression was enhanced in parallel with non-alcoholic steatohepatitis-to-HCC progression.
CONCLUSIONS:
CHOP deficiency attenuated apoptosis, inflammation, fibrosis, and tumorigenesis under fat-loading conditions, indicating that a therapeutic strategy targeting CHOP might be effective for fat-induced liver injury and protecting against promotion of carcinogenesis in patients with liver steatosis.
AuthorsKan Toriguchi, Etsuro Hatano, Kazutaka Tanabe, Kenji Takemoto, Kojiro Nakamura, Yukinori Koyama, Satoru Seo, Kojiro Taura, Shinji Uemoto
JournalJournal of gastroenterology and hepatology (J Gastroenterol Hepatol) Vol. 29 Issue 5 Pg. 1109-18 (May 2014) ISSN: 1440-1746 [Electronic] Australia
PMID24329600 (Publication Type: Journal Article)
Copyright© 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.
Chemical References
  • CCAAT-Enhancer-Binding Proteins
  • Methionine
Topics
  • Aged
  • Aged, 80 and over
  • Animals
  • CCAAT-Enhancer-Binding Proteins (deficiency)
  • Carcinoma, Hepatocellular (etiology, therapy)
  • Choline Deficiency
  • Fatty Liver (etiology, prevention & control, therapy)
  • Female
  • Humans
  • Liver Cirrhosis (etiology, prevention & control, therapy)
  • Liver Neoplasms (etiology, prevention & control, therapy)
  • Male
  • Methionine (deficiency)
  • Mice, Inbred C57BL
  • Middle Aged
  • Molecular Targeted Therapy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: